Royal Philips N.V. 05.22.17
Royal Philips has debuted its TrueVue, GlassVue and aRevealA.I. capabilities on Philips EPIQ 7 and 5 and Affiniti 70 and 50 ultrasound systems. The visualization tools work together to enable photorealistic, transparent and 3D visualization in just one touch, delivering more reproducible and lifelike ultrasound images than traditional technologies.
“Philips’ latest technological advancement in OB/GYN ultrasound is a novel tool allowing clinicians to further explore the anatomic evaluation of the fetus,” said Dr. Michael Ruma, maternal-fetal medicine specialist at Perinatal Associates of New Mexico. “A clinician’s relationship with our patients is at its heart a personal one, especially during pregnancy. The ability to provide high-quality, lifelike images not only helps clinicians improve diagnostic confidence, but also supports the important connection between mother and fetus.”
With the enhanced clinical and workflow offerings of TrueVue, GlassVue and aRevealA.I., clinicians are able to focus on the patient rather than the ultrasound system and diagnose complex obstetric and gynecological situations earlier and with greater confidence. The new OB/GYN suite of innovations offers greater insight for clinicians so that they may elevate patient care, even for patients that are the most difficult to image technically. The suite of visualization tools includes:
“Philips is focused on ultrasound innovation that matters most to clinicians and their patients,” said Vitor Rocha, Ultrasound Business leader at Philips. “We understand what OB/GYN doctors need and how they work, and we aim to design offerings that deliver clinical value and integrate seamlessly into their practice.”
On the EPIQ and Affiniti ultrasound systems, Philips now also offers MaxVue high definition display and enhanced active native data. For the first time ever, MaxVue allows clinicians to experience ultrasound imaging in 16:9 Full High Definition (FHD). Its advanced display capabilities offer clinicians an improved view of ultrasound images during interventional procedures, with over 1 million more pixels than standard format mode. Philips’ enhanced active native data allows post processing of many exam parameters, allowing clinicians to finalize images before transfer to PACS.
Royal Philips is a health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of 17.4 billion euros and employs approximately 70,000 employees with sales and services in more than 100 countries.
“Philips’ latest technological advancement in OB/GYN ultrasound is a novel tool allowing clinicians to further explore the anatomic evaluation of the fetus,” said Dr. Michael Ruma, maternal-fetal medicine specialist at Perinatal Associates of New Mexico. “A clinician’s relationship with our patients is at its heart a personal one, especially during pregnancy. The ability to provide high-quality, lifelike images not only helps clinicians improve diagnostic confidence, but also supports the important connection between mother and fetus.”
With the enhanced clinical and workflow offerings of TrueVue, GlassVue and aRevealA.I., clinicians are able to focus on the patient rather than the ultrasound system and diagnose complex obstetric and gynecological situations earlier and with greater confidence. The new OB/GYN suite of innovations offers greater insight for clinicians so that they may elevate patient care, even for patients that are the most difficult to image technically. The suite of visualization tools includes:
- TrueVue photorealistic 3D visualization, with its virtual light source, is a proprietary advanced 3D ultrasound display method that delivers lifelike 3D ultrasound images and gives the operator the ability to move the light source anywhere in the 3D volume.
- GlassVue transparent 3D visualization, with its internal light source, provides an early, more transparent view of the fetal anatomy than traditional ultrasound. It goes beyond the surface to reveal bone, organs and other internal structures.
- aReveal Anatomically Intelligent Ultrasound (AIUS) 3D fetal face algorithm automatically removes extraneous information to quickly and easily reveal the 3D fetal face. One touch reveals the fetal face, and one touch reverses the process.
“Philips is focused on ultrasound innovation that matters most to clinicians and their patients,” said Vitor Rocha, Ultrasound Business leader at Philips. “We understand what OB/GYN doctors need and how they work, and we aim to design offerings that deliver clinical value and integrate seamlessly into their practice.”
On the EPIQ and Affiniti ultrasound systems, Philips now also offers MaxVue high definition display and enhanced active native data. For the first time ever, MaxVue allows clinicians to experience ultrasound imaging in 16:9 Full High Definition (FHD). Its advanced display capabilities offer clinicians an improved view of ultrasound images during interventional procedures, with over 1 million more pixels than standard format mode. Philips’ enhanced active native data allows post processing of many exam parameters, allowing clinicians to finalize images before transfer to PACS.
Royal Philips is a health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of 17.4 billion euros and employs approximately 70,000 employees with sales and services in more than 100 countries.
